Palisade Bio, Inc.
(NASDAQ : CUR)

( )
CUR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.35%165.880.7%$1319.26m
LLYEli Lilly & Co. -0.65%332.001.1%$1036.01m
PFEPfizer Inc. -0.10%44.350.9%$800.44m
BMYBristol-Myers Squibb Co. 0.00%72.061.0%$784.71m
ABBVAbbVie, Inc. 0.02%144.591.9%$781.87m
MRKMerck & Co., Inc. -0.50%86.360.7%$699.47m
AZNAstraZeneca Plc -0.27%54.541.0%$435.86m
NVSNovartis AG -0.21%76.150.2%$220.80m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%210.768.2%$210.83m
GSKGSK Plc -0.90%29.190.3%$204.18m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.115.4%$190.67m
NVONovo Nordisk A/S 1.18%100.550.1%$177.66m
HZNPHorizon Therapeutics Plc -0.55%63.495.4%$169.03m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.13%152.140.0%$158.36m
SGENSeagen Inc. 0.00%137.725.7%$129.81m

Company Profile

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.